Eyeworld Supplements

1 | WHITE PAPER | JULY 2021 Introduction Dry eye disease (DED) is a common and multi- factorial inflammatory disease of the ocular sur- face characterized by a deficiency in quality and/ or quantity of the tear fluid. 1 The multifactorial nature of DED involves several interrelated un- derlying pathologies, including the loss of ho- meostasis, instability and hyperosmolarity of the tears, and chronic eye inflammation that leads to the neurosensory dysfunction and visual distur- bance. Accordingly, DED is usually manifested by dryness, grittiness, scratchiness, soreness, irrita- tion, burning, watering, foreign body sensation, eye fatigue, and reduced functional visual acuity. Significantly impaired performance of vision de- pendent daily activities (reading, writing, driv- ing) often diminishes the quality of life of DED patients. 2 A detrimental immune response has played a crucially important role in the development and progression of DED. Accordingly, DED-related symptoms are often observed in patients who suf- fer from chronic inflammatory and systemic auto- immune diseases (Sjögren's syndrome, rheuma- toid arthritis, systemic lupus erythematosus). 3–7 Considering the important role of inflammation in DED development, the main treatment strategy has shifted from hydration and lubrication of the dry ocular surface to the immunoregulation-based therapeutic approach, which is designed to break the vicious cycle of chronic inflammation in the by Marguerite McDonald, MD, clinical professor of ophthalmology, NYU Langone Medical Center, New York, New York; clinical professor of ophthalmology, Tulane University Health Sciences Center, New Orleans, Louisiana; cornea/cataract/refractive surgeon and director of the dry eye center of excellence, OCLI Vision, Oceanside, New York; and Carl Randall Harrell, MD, Regenerative Processing Plant, Palm Harbor, Florida Abstract Dry eye disease (DED) is a common and multifactorial disease of the ocular surface characterized by a deficiency in quality and/ or quantity of the tear fluid. A detrimental immune response has an important role in the development and progression of DED. Dr. Harrell recently developed Regener-Eyes ® (generic name "derived-Multiple Allogeneic Proteins Paracrine Signaling [d-MAPPS]"), an ophthalmic solution that contains a large number of immunoregulatory factors that are capable of penetrating the ocular surface and to efficiently attenuate the detrimental immune response in the eye, promoting repair and regeneration of injured tissue. Regener-Eyes ® efficiently alleviated DED-related symptoms (dryness, grittiness, scratchiness, soreness, irritation, burning, watering, foreign body sen- sation, eye fatigue) and improved functional visual acuity in 131 DED patients, without caus- ing any side effects. 12 Herewith, we described in detail the molecular mechanisms and sig- naling pathways that are responsible for the immunomodulatory effects of Regener-Eyes ® , thereby exploring the therapeutic potential of Regener-Eyes ® in the treatment of DED. Sponsored by Regener-Eyes ® WHITE PAPER ASCRS Therapeutic potential of Regener-Eyes ® Ophthalmic Solution in the treatment of dry eye disease

• Cover